Rash from antiepileptic drugs: influence by gender, age, and learning disability
- PMID: 17484761
- DOI: 10.1111/j.1528-1167.2007.01109.x
Rash from antiepileptic drugs: influence by gender, age, and learning disability
Abstract
Purpose: Cutaneous adverse reactions from antiepileptic drugs (AEDs) are common, but have received little scientific attention from a clinical point of view. We wanted to study the incidence of skin reactions of current AEDs and to explore their relation to clinical parameters such as gender, age, and learning disability.
Methods: Consecutive patients with epilepsy were studied retrospectively. A detailed survey of medical records concerning all treatment with AEDs was performed.
Results: A total of 663 patients were included with altogether 2,567 exposures to 15 different AEDs. Skin reactions were found in 14% of the patients and in 5% of the exposures. Ninety-seven percent of the reactions occurred to either carbamazepine (CBZ, 11%), phenytoin (PHT, 8%), lamotrigine (LTG, 8%), oxcarbazepine (8%), or phenobarbital (2%). Skin reactions developed significantly more often in females than in males (19% vs. 8%), and significantly less often in patients with learning disability than in other patients (7% vs. 16%). These differences were significant for CBZ, PHT, and LTG when analyzed separately. Females displayed higher rash frequency during the reproductive years, while men experienced less frequent rash in the same phase of life.
Conclusions: Fertile females have a higher risk for skin reactions compared to males, probably due to hormonal factors. Patients with learning disability appeared to have a lower risk than other patients in this study. Hygiene factors may possibly be underlying.
Similar articles
-
Cross-reactivity of skin rashes with current antiepileptic drugs in Chinese population.Seizure. 2010 Nov;19(9):562-6. doi: 10.1016/j.seizure.2010.09.003. Seizure. 2010. PMID: 20888266
-
Adverse effects of carbamazepine, phenytoin, valproate and lamotrigine monotherapy in epileptic adult Chinese patients.Clin Neurol Neurosurg. 2010 May;112(4):291-5. doi: 10.1016/j.clineuro.2009.12.014. Epub 2010 Jan 13. Clin Neurol Neurosurg. 2010. PMID: 20071075
-
Cross-reactivity pattern of rash from current aromatic antiepileptic drugs.Epilepsy Res. 2008 Aug;80(2-3):194-200. doi: 10.1016/j.eplepsyres.2008.04.003. Epub 2008 May 19. Epilepsy Res. 2008. PMID: 18490142
-
Risk of a lamotrigine-related skin rash: current meta-analysis and postmarketing cohort analysis.Seizure. 2015 Feb;25:52-61. doi: 10.1016/j.seizure.2014.12.001. Epub 2014 Dec 23. Seizure. 2015. PMID: 25645637 Review.
-
Lamotrigine-associated rash: risk/benefit considerations in adults and children.Epilepsia. 1999 Jul;40(7):985-91. doi: 10.1111/j.1528-1157.1999.tb00807.x. Epilepsia. 1999. PMID: 10403224 Review.
Cited by
-
Drug-Induced Severe Cutaneous Adverse Reactions: Insights Into Clinical Presentation, Immunopathogenesis, Diagnostic Methods, Treatment, and Pharmacogenomics.Front Pharmacol. 2022 Apr 20;13:832048. doi: 10.3389/fphar.2022.832048. eCollection 2022. Front Pharmacol. 2022. PMID: 35517811 Free PMC article. Review.
-
HLA Risk Alleles in Aromatic Antiepileptic Drug-Induced Maculopapular Exanthema.Front Pharmacol. 2021 May 26;12:671572. doi: 10.3389/fphar.2021.671572. eCollection 2021. Front Pharmacol. 2021. PMID: 34122097 Free PMC article.
-
Rash in four patients with brain tumor-related epilepsy in monotherapy with oxcarbazepine, during radiotherapy.J Neurol. 2010 Nov;257(11):1939-40. doi: 10.1007/s00415-010-5637-x. Epub 2010 Jul 8. J Neurol. 2010. PMID: 20614129 No abstract available.
-
Implementation of HLA-B*15:02 Genotyping as Standard-of-Care for Reducing Carbamazepine/Oxcarbazepine Induced Cutaneous Adverse Drug Reactions in Thailand.Front Pharmacol. 2022 Jul 5;13:867490. doi: 10.3389/fphar.2022.867490. eCollection 2022. Front Pharmacol. 2022. PMID: 35865943 Free PMC article.
-
Adverse Cutaneous Drug Reactions Associated with Old- and New- Generation Antiepileptic Drugs Using the Japanese Pharmacovigilance Database.Clin Drug Investig. 2019 Apr;39(4):363-368. doi: 10.1007/s40261-019-00754-z. Clin Drug Investig. 2019. PMID: 30689189
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical